{"id":"tislelizumab-adjuvant","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"fatigue"},{"rate":"10-20%","effect":"diarrhea"},{"rate":"10-20%","effect":"nausea"},{"rate":"10-20%","effect":"pyrexia"},{"rate":"5-10%","effect":"hypothyroidism"},{"rate":"5-10%","effect":"decreased appetite"},{"rate":"5-10%","effect":"dyspnea"},{"rate":"5-10%","effect":"cough"},{"rate":"5-10%","effect":"headache"},{"rate":"5-10%","effect":"muscle weakness"}]},"_chembl":{"chemblId":"CHEMBL4297840","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on the surface of tumor cells. This blockade prevents the inhibition of T-cell activation and proliferation, allowing the immune system to recognize and attack cancer cells more effectively.","oneSentence":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:58.618Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of esophageal squamous cell carcinoma"},{"name":"Adjuvant treatment of colorectal cancer"}]},"trialDetails":[{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT07120282","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-28","conditions":"Lung Cancer (NSCLC)","enrollment":108},{"nctId":"NCT07136077","phase":"PHASE2","title":"A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-18","conditions":"Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer","enrollment":20},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT05116085","phase":"PHASE2","title":"Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2022-01-26","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT07402538","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":184},{"nctId":"NCT07373990","phase":"PHASE3","title":"Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-15","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":418},{"nctId":"NCT05254847","phase":"PHASE2","title":"Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-02-24","conditions":"Biliary Tract Cancer","enrollment":65},{"nctId":"NCT07341360","phase":"EARLY_PHASE1","title":"Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-10-13","conditions":"Pseudomyxoma Peritonei","enrollment":10},{"nctId":"NCT07330037","phase":"PHASE2","title":"TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-01","conditions":"NSCLC","enrollment":41},{"nctId":"NCT07320105","phase":"PHASE4","title":"Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-15","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07304258","phase":"PHASE2","title":"A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University","startDate":"2025-12-12","conditions":"Gastric Cancer Peritoneal Metastases","enrollment":30},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT07264647","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2025-03-27","conditions":"Stage III NSCLC","enrollment":30},{"nctId":"NCT06914011","phase":"PHASE3","title":"Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-01-06","conditions":"Esophageal Cancer","enrollment":172},{"nctId":"NCT05507658","phase":"PHASE2","title":"Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2022-07-18","conditions":"Locally Advanced Gastric Adenocarcinoma","enrollment":28},{"nctId":"NCT07243938","phase":"PHASE2","title":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-15","conditions":"Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC)","enrollment":70},{"nctId":"NCT07243691","phase":"NA","title":"Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-12-01","conditions":"Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT06467799","phase":"PHASE2","title":"Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma, Beyond Milan Criteria","enrollment":39},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT07145931","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy","enrollment":24},{"nctId":"NCT07132008","phase":"PHASE3","title":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2025-10-01","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":94},{"nctId":"NCT07109401","phase":"PHASE2","title":"Perioperative Immunotherapy for Resectable Limited-Stage SCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT04570410","phase":"PHASE2","title":"Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-12-01","conditions":"Bladder Urothelial Carcinoma","enrollment":30},{"nctId":"NCT07089199","phase":"PHASE2","title":"Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-25","conditions":"NSCLC, Tislelizumab, Anlotinib","enrollment":34},{"nctId":"NCT07067268","phase":"PHASE2","title":"Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-09-14","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":76},{"nctId":"NCT07067450","phase":"NA","title":"Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-07-20","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":98},{"nctId":"NCT06617936","phase":"PHASE2","title":"Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"Hua Zhang","startDate":"2024-08-27","conditions":"Unresectable Non-small Cell Lung Cancer","enrollment":36},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT06939439","phase":"PHASE3","title":"Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-01","conditions":"Gastric Cancer Stage III","enrollment":416},{"nctId":"NCT06009861","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Hospital of Stomatology","startDate":"2023-06-27","conditions":"Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma","enrollment":110},{"nctId":"NCT06997913","phase":"","title":"Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）","status":"ENROLLING_BY_INVITATION","sponsor":"Hengchao Yu","startDate":"2025-03-15","conditions":"Lymph Node Metastasis, Neurovascular Invasion, Pathology Showed R1 Resection","enrollment":10},{"nctId":"NCT06990178","phase":"NA","title":"Adaptive Neoadjuvant Therapy for Esophageal Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2028-03-01","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":43},{"nctId":"NCT06978829","phase":"PHASE2","title":"Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-03-01","conditions":"LA HNSCC","enrollment":42},{"nctId":"NCT06957938","phase":"PHASE3","title":"Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-04-28","conditions":"Laryngeal Carcinoma, Hypopharyngeal Carcinoma","enrollment":168},{"nctId":"NCT06420440","phase":"PHASE2","title":"Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model","status":"RECRUITING","sponsor":"Chen Xiaoping","startDate":"2024-06-01","conditions":"HCC","enrollment":160},{"nctId":"NCT06939127","phase":"PHASE2","title":"Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-04-01","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":38},{"nctId":"NCT05984602","phase":"PHASE1","title":"A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-07-14","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT06685887","phase":"PHASE2","title":"A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02-15","conditions":"Gastric Cancer","enrollment":34},{"nctId":"NCT06258811","phase":"PHASE3","title":"Neoadjuvant Immunochemotherapy for LAOSCC","status":"RECRUITING","sponsor":"Lai-ping Zhong","startDate":"2024-02-20","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma","enrollment":134},{"nctId":"NCT06344156","phase":"PHASE1","title":"Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-04-01","conditions":"Pancreatic Cancer, Adjuvant Therapy","enrollment":43},{"nctId":"NCT06664021","phase":"PHASE2","title":"Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-11-16","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":60},{"nctId":"NCT04615143","phase":"PHASE2","title":"Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Recurrent Hepatocellular Carcinoma","enrollment":80},{"nctId":"NCT06760858","phase":"","title":"A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":122},{"nctId":"NCT06728618","phase":"PHASE2","title":"Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-12","conditions":"Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Resectable Oral and Oropharyngeal Squamous Cell Carcinoma","enrollment":28},{"nctId":"NCT06725498","phase":"PHASE2","title":"Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-12-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06696742","phase":"PHASE2","title":"PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-02-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":60},{"nctId":"NCT06520683","phase":"PHASE3","title":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":180},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT05724329","phase":"PHASE2","title":"Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-02-05","conditions":"Head and Neck Squamous Cell Carcinomas","enrollment":24},{"nctId":"NCT05086627","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2021-09-01","conditions":"Locally Advanced Rectal Cancer","enrollment":118},{"nctId":"NCT06560528","phase":"PHASE2","title":"Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":40},{"nctId":"NCT06554028","phase":"PHASE2","title":"Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-08","conditions":"Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms","enrollment":46},{"nctId":"NCT06353360","phase":"PHASE2","title":"TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.","status":"RECRUITING","sponsor":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","startDate":"2024-04-30","conditions":"Glioblastoma Multiforme","enrollment":30},{"nctId":"NCT06475755","phase":"PHASE2","title":"Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-06-30","conditions":"Non-Small Cell Lung Cancer, Anti Angiogenesis","enrollment":178},{"nctId":"NCT06451211","phase":"PHASE2","title":"Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-17","conditions":"Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach","enrollment":53},{"nctId":"NCT06323369","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":154},{"nctId":"NCT05582265","phase":"PHASE3","title":"Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-10-28","conditions":"Head and Neck Squamous Cell Carcinomas","enrollment":537},{"nctId":"NCT06375109","phase":"PHASE2","title":"PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital, Capital Medical University","startDate":"2024-04-16","conditions":"Limited-stage Small-cell Lung Cancer","enrollment":60},{"nctId":"NCT05211232","phase":"PHASE3","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-10","conditions":"Nasopharyngeal Carcinoma","enrollment":450},{"nctId":"NCT06366945","phase":"PHASE2","title":"Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-04-20","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, HNSCC","enrollment":85},{"nctId":"NCT06357598","phase":"PHASE4","title":"Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2024-01-18","conditions":"Non-small-cell Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT06266871","phase":"PHASE1, PHASE2","title":"SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-03-10","conditions":"Gastric Cancer","enrollment":64},{"nctId":"NCT06238167","phase":"PHASE2","title":"Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-04-01","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT05910970","phase":"PHASE3","title":"Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2024-02-15","conditions":"Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor","enrollment":200},{"nctId":"NCT06118658","phase":"PHASE2","title":"Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2023-11-01","conditions":"Gastric, Colorectal Adenocarcinoma","enrollment":30},{"nctId":"NCT06059885","phase":"PHASE2","title":"Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2021-12-22","conditions":"Liver Neoplasms","enrollment":60},{"nctId":"NCT06056336","phase":"PHASE2","title":"Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Guo Xufeng","startDate":"2023-09-07","conditions":"Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy","enrollment":73},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT05984342","phase":"PHASE1","title":"Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2023-08-02","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT05564338","phase":"PHASE3","title":"Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"BeiGene","startDate":"2023-06-30","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT05841134","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-06-01","conditions":"MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin","enrollment":25},{"nctId":"NCT04542369","phase":"PHASE2","title":"Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2021-05-01","conditions":"Small-cell Lung Cancer","enrollment":15},{"nctId":"NCT05687357","phase":"PHASE2","title":"Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-03-15","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":140},{"nctId":"NCT05807776","phase":"PHASE2","title":"Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-01","conditions":"Resectable Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT05407519","phase":"PHASE2","title":"A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2022-07-25","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05286957","phase":"PHASE2","title":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-06-20","conditions":"NSCLC","enrollment":60},{"nctId":"NCT05445648","phase":"PHASE2","title":"Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-02","conditions":"Urinary Bladder Neoplasms","enrollment":65},{"nctId":"NCT05620498","phase":"PHASE2","title":"Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-09-08","conditions":"Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","enrollment":60},{"nctId":"NCT05546619","phase":"NA","title":"Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection","status":"UNKNOWN","sponsor":"Sulai Liu","startDate":"2022-08-01","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05545124","phase":"PHASE2","title":"Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2022-11","conditions":"Hepatocellular Carcinoma","enrollment":32},{"nctId":"NCT04782804","phase":"PHASE1, PHASE2","title":"Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01-01","conditions":"Cholangiocarcinoma, Intrahepatic","enrollment":30},{"nctId":"NCT05469061","phase":"PHASE2","title":"Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma","enrollment":17},{"nctId":"NCT05448885","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-09-01","conditions":"Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT05394415","phase":"PHASE1, PHASE2","title":"Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-05-01","conditions":"Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation","enrollment":30},{"nctId":"NCT05342792","phase":"PHASE3","title":"Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-04-17","conditions":"Nasopharyngeal Carcinoma","enrollment":556},{"nctId":"NCT05244837","phase":"PHASE2","title":"Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC","status":"UNKNOWN","sponsor":"Hao Long","startDate":"2020-12-22","conditions":"Tislelizumab, Safety, Biomarker","enrollment":100},{"nctId":"NCT05231850","phase":"PHASE2","title":"A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-03-01","conditions":"Colon Cancer","enrollment":70},{"nctId":"NCT04981665","phase":"PHASE2","title":"A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2021-11-08","conditions":"Hepatocellular Carcinoma, Adjuvant Therapy","enrollment":50},{"nctId":"NCT04815408","phase":"PHASE2","title":"PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-04-01","conditions":"Ovarian Cancer, Neoadjuvant Chemotherapy, Anti-PD-1","enrollment":40},{"nctId":"NCT04498793","phase":"PHASE2","title":"Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-09","conditions":"HER2-negative Breast Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tislelizumab（adjuvant）","genericName":"Tislelizumab（adjuvant）","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. Used for Adjuvant treatment of esophageal squamous cell carcinoma, Adjuvant treatment of colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}